Smith Kline & French Laboratories Limited

Societe Civile Bioprojet

Institut National De La Sante Et De La Recherche Medicale

Other

Societe Civile Bioproject

Vanguard Medica Limited

Charon R Ganellin

Graham J Durant

John C Emmett

Rodney C Young

Thomas H Brown

George S Sach

Hunter Douglas Prain

Geoffrey R Owen

Robert John Ife

Jean-Charles Schwartz

Jean-Michel Arrang

Monique Garbarg

Margaret R Vickers

Jeanne-Marie Lecomte

George R White

Walter Schunack

Holger Stark

David A Owen

Xavier Ligneau

James Whyte Black

Sigurd Elz

Fabien Leurquin

Ralph Lipp

Michael Edward Parsons

Katja Purand

Abdellatif Fkyerat

Wasyl Tertiuk

Froylan Vargas

Paul Beaumont Bishop

Lihua Zhao

Bertrand Leblond

Christiane Rose

David Jack

Bryan Colin Jones

Bruce Everett Davison

Pierre Bourgeat

Torben Hesselbo

Ramesh B Bambal

Andrew N J Moore

Suzanne Chan

Yondjun Chen

Samad Sanjeeda

Jeanne-Marie Lecounte

Rose Christiania

Walter G Schunacx

Hulger Stark

Use of a compound of formula (A), wherein: W is a residue which imparts antagonistic and/or agonistic activity at histamine H-receptors when attached to an imidazole ring in 4(5) position; Rand Rmay be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H-receptors of histamine.

[object Object]

Use of a compound of formula (A), wherein: W is a residue which imparts antagonistic and/or agonistic activity at histamine H-receptors when attached to an imidazole ring in 4(5) position; Rand Rmay be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H-receptors of histamine 

Tripeptidylpeptidase inhibitors

The invention is relative to a compound of formula (I) and its use as an inhibitor of the CCK-inactivating peptidase tripeptidyl peptidase (TPP II). The invention concerns in particular the treatment of eating disorder, obesity, psychotic syndrome and associated psychiatric disorders. It concerns also the cosmetic use of a compound (I) in particular to aid slimming.

Tripeptidyl peptidase inhibitors

The present invention relates to compounds which are useful as sunscreens. The compounds persist on the skin for much longer than conventional sunscreens because they comprise a Michael acceptor linked directly or indirectly to a chromophore. The Michael acceptor is capable of undergoing a conjugate addition reaction with thiol groups present in cysteine residues of keratin and thus the compound is chemically bound to the skin and will not be removed by immersion in water.

Compounds containing a michael-acceptor, especially maleimide or maleic

A compound selected from the group consisting of a compound of the formula ##STR1## having antagonist properties to histamine H.sub.3 -receptors.

Imidazole derivatives for pharmaceutical use

Imidazole compounds and their therapeutic applications

S-(Aminoalkyl)isothioureas which have immunosuppressant activity. Two specific compounds are 2-(3-dimethylaminopropylthio)-2-imidazoline and N,N'-dimethyl-S-(3-dimethylaminopropyl)isothiourea.

Pharmaceutical compositions

The compounds are isoureas and isothioureas which have an O- or S-alkylpyrimidone substituent and which are histamine H.sub.2 -antagonists and antiinflammatory agents. A specific compound of this invention is 2-[5-(O-isoureido)pentylamino]-5-(6-methyl-3-pyridylmethyl)-4-pyrimidone.

2-substituted alkylaminopyrimidones useful as H.sub.2 -antagonists and

Heterocyclic compounds which are inhibitors of histamine activity, in particular, inhibitors of H-2 histamine receptors. A specific compound of this invention is 2-[2-(4-methyl-5-imidazolymethylthio)ethylamino]-4-pyrimidone.

Pharmacologically active compounds

Heterocyclic compounds which are inhibitors of histamine activity, in particular, inhibitors of H-2 histamine receptors. A specific compound of this invention is 2-[2-(4-methyl-5-imidazolylmethylthio)ethylamino]-4-pyrimidone.

Heterocyclic alkylaminoheterocycles

The compounds are C.sub.2 -C.sub.8 straight chain alkanes terminally substituted, symmetrically or unsymmetrically, by N-(N'-substituted guanidino), N-(N',N'-disubstituted guanidino). N-(N'-substituted thioureido), N-(nitromethylene amidino) or S-(N-substituted isothioureido) groups. Two compounds of the invention are 1,3-bis-[N'-(2-(5-methyl-4-imidazolylmethylthio)ethyl)guanidino]propane and 1,3-bis-[S-(N-2-(5-methyl-4-imidazolylmethylthio)ethyl)isothioureido]p ropane. The compounds of this invention are inhibitors of H-2 histamine receptors.

Unsymmetrical guanidino, thioureido, isothioureido and

The compounds are isoureas and isothioureas which have an O- or S- alkylpyrimidone substituent and which are histamine H.sub.2 -antagonists and antiinflammatory agents. A specific compound of this invention is 2-[5-(O-isoureido)pentylamino]-5-(6-methyl-3-pyridylmethyl)-4-pyrimidone.

2-Substituted alkylaminopyrimidones

Growing community of inventors

Welwyn Garden City, United Kingdom

Charon R Ganellin